| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received on August 20, 2005
Accepted on December 13, 2005
Hemostasis and Thrombosis |
1 Department of Medicine III, University of Heidelberg, Heidelberg, Germany
* To whom correspondence should be addressed. E-mail: Boris.Ivandic{at}med.uni-heidelberg.de.
Background: Inhibition of platelet aggregation by clopidogrel may be insufficient in up to 30% of users. These nonresponders carry an increased risk of cardiovascular events. We reported here a simple assay to study clopidogrel responsiveness.
Methods: Electrical impedance aggregometry was performed in diluted whole blood in the presence of 5 and 20 µmol/L ADP. Some samples were incubated with 0.1 mmol/L methyl-S-adenosine monophosphate (MeSAMP), a P2Y12 receptor blocker, to maximize inhibition of aggregation before aggregometry. To validate the assay, we analyzed 6-min impedance in 21 healthy probands and 244 patients with coronary artery disease (CAD).
Results: At 5 µmol/L ADP, the imprecision of the assay was 11%. Mean (SD) impedance of the healthy cohort was 12.2 (2.2) 
. The mean - 3 SD was used to define the cutoff for clopidogrel responsiveness: responders and nonresponders exhibited a 6-min impedance 
5 and >5 , respectively. Samples from nonresponders were incubated with MeSAMP and analyzed again to distinguish pharmacokinetic and pharmacodynamic types of resistance. Sixteen percent of CAD patients were classified as nonresponders (38 and 2 cases of pharmacokinetic and pharmacodynamic resistance, respectively). Female sex was strongly associated with clopidogrel resistance (P = 0.0002, Fisher exact test). A higher clopidogrel loading dose (P = 0.0353, Mann-Whitney U-test) was given to responders (median, 450 mg) than nonresponders (median, 300 mg). Age and cardiovascular diagnosis showed no significant associations.
Conclusions: Impedance aggregometry using 5 µmol/L ADP is a useful tool for studying clopidogrel responsiveness. MeSAMP allows characterization of responsiveness "on treatment" and may be useful for optimizing clopidogrel dosing.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  R. Paniccia, E. Antonucci, N. Maggini, E. Romano, A. M. Gori, R. Marcucci, D. Prisco, and R. Abbate Assessment of Platelet Function on Whole Blood by Multiple Electrode Aggregometry in High-Risk Patients With Coronary Artery Disease Receiving Antiplatelet Therapy Am J Clin Pathol, June 1, 2009; 131(6): 834 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. T. Ivandic, M. Sausemuth, H. Ibrahim, E. Giannitsis, M. Gawaz, and H. A. Katus Dual Antiplatelet Drug Resistance Is a Risk Factor for Cardiovascular Events after Percutaneous Coronary Intervention Clin. Chem., June 1, 2009; 55(6): 1171 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H.R. Rao Need for a Point-of-Care Assay for Monitoring Antiplatelet and Antithrombotic Therapies Stroke, June 1, 2009; 40(6): 2271 - 2272. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lordkipanidze, C. Pharand, T. A. Nguyen, E. Schampaert, D. A. Palisaitis, and J. G. Diodati Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients Eur. Heart J., December 1, 2008; 29(23): 2877 - 2885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Muller-Schunk, J. Linn, N. Peters, M. Spannagl, M. Deisenberg, H. Bruckmann, and T.E. Mayer Monitoring of Clopidogrel-Related Platelet Inhibition: Correlation of Nonresponse with Clinical Outcome in Supra-Aortic Stenting AJNR Am. J. Neuroradiol., April 1, 2008; 29(4): 786 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. T. Ivandic, E. Giannitsis, P. Schlick, P. Staritz, H. A. Katus, and T. Hohlfeld Determination of Aspirin Responsiveness by Use of Whole Blood Platelet Aggregometry Clin. Chem., April 1, 2007; 53(4): 614 - 619. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
